Trial site
National Institute For Infectious Diseases Lazzaro Spallanzani
Rome, 00149, ItalyNot linked to an institution yet
- 10running trials
- 7closed trials
The trials here
What the 18 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 26 trials
- Phase 2/32 trials
- Status
- Completed7 trials
- Active, not recruiting6 trials
- Not yet recruiting3 trials
- Recruiting1 trial
- Suspended1 trial
- Lead sponsor
- Gilead Sciences Inc.6 trials
- ViiV Healthcare4 trials
- Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida1 trial
- F2G Ltd1 trial
- GlaxoSmithKline1 trial
- and 5 more
Running trials
Recruiting
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
2025-524335-39-00· Phase 3· Gilead Sciences Inc.· Source
Recruiting
Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens
2025-524336-19-00· Phase 3· Gilead Sciences Inc.· Source
Recruiting
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
NCT07202546· Phase 2· ViiV Healthcare· Source
Active, not recruiting
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
NCT06694805· Phase 3· ViiV Healthcare· Source
Recruiting
Phase II study on the safety and efficacy of cysteamine in association with standard tuberculosis therapy for the treatment of patients with pulmonary tuberculosis: a new therapy for tuberculosis directed at the host.
2024-516088-10-00· Phase 2· National Institute For Infectious Diseases Lazzaro Spallanzani· Source
Recruiting
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
NCT06333808· Phase 3· Gilead Sciences Inc.· Source
Active, not recruiting
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
NCT06497504· Phase 2· GlaxoSmithKline· Source
Active, not recruiting
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen
NCT05502341· Phase 2/3· Gilead Sciences Inc.· Source
Active, not recruiting
Early DOlutegravir/LAmivudine Switching after virological suppression (EDOLAS Study)
2024-518909-18-00· Phase 3· Societa Italiana Di Malattie Infettive E Tropicali SIMIT· Source
Recruiting
HIV-1 Infected Patients, Phase II Trial, Dual Combination Doravirine/Raltegravir Open Label
NCT04513626· Phase 2· Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error